PUBLISHER: The Business Research Company | PRODUCT CODE: 2035846
PUBLISHER: The Business Research Company | PRODUCT CODE: 2035846
Biofoundry-as-a-service is a model that provides access to automated, high-throughput biological engineering facilities through remote or digital interfaces. It allows the design, construction, and testing of genetic constructs and organisms without extensive in-house infrastructure. This service accelerates synthetic biology workflows by integrating robotics, software, and data analytics into a unified platform.
The essential service types of biofoundry-as-a-service include design, build, test, learn, and integrated services. Design involves planning and engineering biological systems using automated workflows and computational tools. Applications include pharmaceuticals, agriculture, industrial biotechnology, environmental sectors, and others, serving academic and research institutes, biotechnology companies, pharmaceutical firms, and other end-users.
Tariffs on imported laboratory automation equipment, robotic systems, and analytical instruments are impacting the biofoundry-as-a-service market by increasing setup and operational costs, particularly affecting design, build, and test service segments. Regions such as North America, Europe, and Asia-Pacific, which rely on imported high-precision instruments and robotics, are most affected. While tariffs increase costs, they also incentivize local manufacturing, promote domestic service capabilities, and encourage innovation in cost-efficient, automated bioengineering platforms, creating growth opportunities for regional providers.
The biofoundry-as-a-service market research report is one of a series of new reports from The Business Research Company that provides biofoundry-as-a-service market statistics, including biofoundry-as-a-service industry global market size, regional shares, competitors with a biofoundry-as-a-service market share, detailed biofoundry-as-a-service market segments, market trends and opportunities, and any further data you may need to thrive in the biofoundry-as-a-service industry. This biofoundry-as-a-service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The biofoundry-as-a-service market size has grown exponentially in recent years. It will grow from $1.65 billion in 2025 to $2.01 billion in 2026 at a compound annual growth rate (CAGR) of 21.3%. The growth in the historic period can be attributed to increasing investment in synthetic biology, adoption of automated laboratory equipment, rising demand for genetic engineering services, growth of academic and research institutes, expansion of biotechnology companies.
The biofoundry-as-a-service market size is expected to see exponential growth in the next few years. It will grow to $4.38 billion in 2030 at a compound annual growth rate (CAGR) of 21.6%. The growth in the forecast period can be attributed to growing deployment of AI-driven biofoundry platforms, increasing adoption of cloud-based design-build-test-learn services, rising demand for integrated bioengineering solutions, expansion of pharmaceutical and industrial biotechnology applications, increasing focus on scalable and high-throughput biofoundry operations. Major trends in the forecast period include increasing adoption of end-to-end dbtl cycle services, rising demand for automated dna assembly services, growing integration of machine learning modeling in biofoundries, expansion of platform-as-a-service bioengineering solutions, rising focus on high-throughput phenotypic and genotypic testing.
The increasing investments in life sciences are anticipated to drive the growth of the biofoundry-as-a-service market in the future. Investments in life sciences refer to funding or allocating capital to companies, research, and technologies focused on healthcare, biotechnology, pharmaceuticals, medical devices, and related biological innovations. Such investments are growing due to rising demand for advanced healthcare solutions, as more individuals require innovative treatments, personalized medicine, and cutting-edge technologies to tackle complex diseases and improve overall health outcomes. Investments in life sciences stimulate the growth of biofoundry-as-a-service by providing the capital needed to develop advanced automated platforms, accelerate high-throughput biological research, and deliver scalable, customizable solutions for biotechnology companies and academic institutions. For instance, in September 2025, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based non-profit organization, the UK government pledged up to $707 million (£520 million) in capital grants to support inward investment in innovative life sciences manufacturing, reinforcing the country's position as a leading hub for life sciences innovation. Therefore, the increasing investments in life sciences are driving the growth of the biofoundry-as-a-service market.
Leading companies operating in the biofoundry-as-a-service market are focusing on deploying modular, automated biofoundry platforms to accelerate biologics development, streamline process optimization, and enhance scalable manufacturing capabilities. Modular, automated biofoundry platforms are advanced laboratory systems that integrate robotics, artificial intelligence-enabled software, and standardized biological processes to streamline the design, construction, testing, and optimization of biological systems with minimal manual input. For example, in November 2024, Quotient Sciences, a UK-based drug development and manufacturing accelerator, installed Centillion's GMP Biofoundry-in-a-Box platform to expand its integrated drug development and manufacturing services. The installation enhances the company's ability to provide automated, high-throughput biologics development and GMP-compliant production, supporting clients with accelerated timelines, improved reproducibility, and scalable therapeutic manufacturing solutions.
In December 2023, Synplogen Inc., a gene therapy solutions company based in Japan, partnered with Ginkgo Bioworks Inc. to accelerate DNA manufacturing and gene therapy platform services in Japan. This partnership aims to increase access to high-quality DNA materials, streamline gene therapy development, and support innovative therapeutic programs for rare and complex diseases. Ginkgo Bioworks Inc., based in the US, is a biotechnology company that specializes in offering biofoundry-as-a-service (BFaaS).
Major companies operating in the biofoundry-as-a-service market are GenScript Biotech Corporation, Ginkgo Bioworks Holdings Inc., Twist Bioscience Corporation, Codexis Inc., Emerald Cloud Lab Inc., Synbio Technologies LLC, Automata Technologies Limited, Telesis Bio Inc., Culture Biosciences Inc., Bioneer Corporation, Earlham Biofoundry Ltd., Arzeda Corporation, LabGenius Limited, Conagen Inc., Bota Biosciences Inc., Arctoris Ltd., Evonetix Ltd., Absci Corporation, TeselaGen Biotechnology Inc., SynbiCITE Innovation Hub.
North America was the largest region in the biofoundry-as-a-service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biofoundry-as-a-service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the biofoundry-as-a-service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The biofoundry-as-a-service market consists of revenues earned by entities by providing services such as protein expression and analysis, automated cell culture, metabolic pathway optimization, genome editing, enzyme engineering, pathway prototyping, and bioinformatics support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biofoundry-As-A-Service Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses biofoundry-as-a-service market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for biofoundry-as-a-service ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biofoundry-as-a-service market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.